Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233809 | 1.00 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL715472 | 1.00 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL253643 | 0.95 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL231701 | 0.95 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5077752 | 0.90 | PDE5A (0.83) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL237558 | 0.89 | PDE5A (0.87) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL237559 | 0.89 | PDE5A (0.87) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7431010 | 0.89 | PDE5A (0.87) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL714981 | 0.88 | PDE5A (0.85) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL714980 | 0.88 | PDE5A (0.85) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183023-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170128453-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128453-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183023-B2 | Uses | CNTN1, BDNF, SMPD1 | PDE5A 14/4885PDE4A 44/4885PDE4B 62/4885 |
| US-20170128453-A1 | NOVEL USES | BDNF, CNTN1, DCX | PDE5A 28/4885PDE4A 27/4885PDE4B 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.